NCT04781543View on ClinicalTrials.gov

A Multicenter Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients With Diffuse Cutaneous Systemic Sclerosis

PHASE2TerminatedINTERVENTIONAL
Enrollment

301

Participants

Timeline

Start Date

November 4, 2022

Primary Completion Date

February 24, 2025

Study Completion Date

February 24, 2025

Conditions
Diffuse Cutaneous Systemic SclerosisSclerosis, Systemic
Interventions
DRUG

HZN-825 BID

300 mg oral tablets BID

DRUG

Placebo

Placebo BID

DRUG

HZN-825 QD

300 mg oral tablets QD

Trial Locations (4)

11000

Institute of Rheumatology - PPDS, Belgrade

Military Medical Academy, Belgrade

708120

Institute for Treatment and Rehabilitation Niska Banja, Niška Banja

08025

Hospital de La Santa Creu i Sant Pau, Barcelona

Sponsors

Lead Sponsor

Amgen
All Listed Sponsors
lead

Amgen

INDUSTRY